- Home
- CLPS vs CVKD Comparison
CLPS vs CVKD Comparison
Compare CLPS & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPS
- CVKD
- Stock Information
- Founded
- CLPS 2005
- CVKD 2022
- Country
- CLPS Hong Kong
- CVKD United States
- Employees
- CLPS N/A
- CVKD N/A
- Industry
- CLPS Computer Software: Prepackaged Software
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- CLPS Technology
- CVKD Health Care
- Exchange
- CLPS Nasdaq
- CVKD Nasdaq
- Market Cap
- CLPS 26.3M
- CVKD 29.5M
- IPO Year
- CLPS 2018
- CVKD 2023
- Fundamental
- Price
- CLPS $1.00
- CVKD $12.32
- Analyst Decision
- CLPS
- CVKD Strong Buy
- Analyst Count
- CLPS 0
- CVKD 1
- Target Price
- CLPS N/A
- CVKD $32.00
- AVG Volume (30 Days)
- CLPS 11.6K
- CVKD 19.8K
- Earning Date
- CLPS 03-05-2025
- CVKD 08-06-2025
- Dividend Yield
- CLPS 13.13%
- CVKD N/A
- EPS Growth
- CLPS N/A
- CVKD N/A
- EPS
- CLPS N/A
- CVKD N/A
- Revenue
- CLPS $153,816,045.00
- CVKD N/A
- Revenue This Year
- CLPS N/A
- CVKD N/A
- Revenue Next Year
- CLPS N/A
- CVKD N/A
- P/E Ratio
- CLPS N/A
- CVKD N/A
- Revenue Growth
- CLPS 5.81
- CVKD N/A
- 52 Week Low
- CLPS $0.68
- CVKD $5.70
- 52 Week High
- CLPS $1.70
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- CLPS 53.85
- CVKD 38.54
- Support Level
- CLPS $0.90
- CVKD $13.12
- Resistance Level
- CLPS $1.08
- CVKD $15.99
- Average True Range (ATR)
- CLPS 0.06
- CVKD 0.76
- MACD
- CLPS 0.01
- CVKD -0.08
- Stochastic Oscillator
- CLPS 55.56
- CVKD 6.45
About CLPS CLPS Incorporation
CLPS Inc is a holding company. The company through its subsidiaries provides information technology consulting and solutions institutions in the banking, insurance, and financial sectors, both in China and globally. Its products are Risk Control Platform, Transaction Acquiring Platform, Debt Collection Platform, Virtual Bank Training Platform, Credit Card System, and other related products. The company generates its revenue from IT consulting services, Customized IT solution services, and others. Generating the majority of its revenue from the IT consulting service.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.